← 홈

ADC

53개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 53개
ADCBiologicCanadian Cancer Trials GroupPhase 2

Savolitinib (Savolitinib)

Prostate Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 57.1%임상시험 41상태 RECRUITING
ADCBiologicFondazione per la Medicina Pers…Phase 2

Selpercatinib (Selpercatinib)

Breast Cancer; Gastrointestinal Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 100%임상시험 38상태 ACTIVE
ADCBiologicBeijing Biostar Pharmaceuticals…Phase 2

Utidelone (Utidelone)

Non-small Cell Lung Cancer Patients with Brain Metastases · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 36상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 2

Vistusertib (Vistusertib)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 9.5%임상시험 30상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 3

DS-1062a (DS-1062a)

Non-small Cell Lung Cancer · Metastatic Lung Cancer

#MetastaticLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 74%임상시험 28상태 ACTIVE
ADCBiologicstaleEMD Serono Research & Developme…Phase 2

Tepotinib (Tepotinib)

Non-small Cell Lung Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 54.7%임상시험 28상태 ACTIVE
ADCBiologicstaleDaiichi SankyoPhase 1

FL-DP (HER3-DXd, HER3-DXd (FL-DP))

Non-Small Cell Lung Cancer (NSCLC) · HER3

#HER3#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 24상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 1

CTM-1 Lyo-DP (HER3-DXd, HER3-DXd (CTM-1 Lyo-DP))

Non-Small Cell Lung Cancer (NSCLC) · HER3

#HER3#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 22상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 1

CTM-3 Lyo-DP (HER3-DXd, HER3-DXd (CTM-3 Lyo-DP))

Non-Small Cell Lung Cancer (NSCLC) · HER3

#HER3#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 22상태 RECRUITING
ADCBiologicstaleBioNTech SEPhase 3

Pumitamig (Pumitamig)

Non-small Cell Lung Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 19상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 3

Volrustomig (Volrustomig)

Metastatic Non-small Cell Lung Cancer · Endometrial Cancer

#EndometrialCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 19상태 RECRUITING
ADCBiologicstaleShanghai Junshi Bioscience Co.,…Phase 2

JS207 (JS207)

Non-squamous Non-small Cell Lung Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 15상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 2

Danvatirsen (Danvatirsen)

Advanced Colorectal Carcinoma; Advanced Lung Non-Small Cell Carcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 11.1%임상시험 14상태 RECRUITING
ADCBiologicstaleHoffmann-La RochePhase 3

Divarasib (Divarasib)

Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer · Solid Tumors

#SolidTumors#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
임상시험 13상태 RECRUITING
ADCBiologicShanghai Junshi Bioscience Co.,…Phase 2

JS212 (JS212)

Non-squamous Non-small Cell Lung Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 7상태 RECRUITING
ADCBiologicstaleMultitude Therapeutics Inc.Phase 2

AMT-116 (AMT-116)

Advanced Non-small Cell Lung Cancer (NSCLC) · Advanced Non-small Cell Lung Cancer (NSC

#AdvancedNon-smallCellLungCancerN#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 4상태 RECRUITING
ADCBiologicstaleGenentech, Inc.Phase 2

DNIB0600A (DNIB0600A)

Non-Squamous Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer, Ovarian Canc

#Non-SmallCellLungCancerOvarianCa#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 ACTIVE
ADCBiologicstaleAstraZenecaPhase 2

AZD0171 (AZD0171)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 34.9%임상시험 2상태 RECRUITING
ADCBiologicstaleBioNTech SEPhase 2

BNT326 (BNT326)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 2상태 RECRUITING
ADCBiologicstaleEnliven TherapeuticsPhase 1

ELVN-002 (ELVN-002)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · HER2

#HER2#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 2상태 RECRUITING

2 / 3 페이지

← 이전다음 →